HEPA ContraVir Pharmaceuticals Inc.
NewsSee all news
-
Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments
University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion
-
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th
CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual
-
Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments
University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion
-
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Kilmer Lucas Announces Agenda for BioTuesdays Pre-JPM Virtual Conference on December 10th
CAMBRIDGE, ON / ACCESSWIRE / December 3, 2019 / Kilmer Lucas, a healthcare-focused investor relations and capital markets advisory firm, today announced the agenda for its first annual BioTuesdays Pre-JPM Virtual
-
Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
CRV431 has Potently Reduced Fibrosis in all Experimental Models Tested To DateEDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the
-
World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director
EDISON, NJ / ACCESSWIRE / October 10, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from
-
Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions
Collectively, Company's Senior Management Team Has More Than 100 Years of Cyclophilin ExperienceEDISON, NJ / ACCESSWIRE / October 3, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company